UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.697

Sortiert nach

Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients

British journal of haematology, 2016-09, Vol.174 (5), p.711-720

2016

Link zum Volltext

Verfügbarkeit prüfen

Enzymatically Formed Peptide Assemblies Sequestrate Proteins and Relocate Inhibitors to Selectively Kill Cancer Cells

Angewandte Chemie (International ed.), 2020-09, Vol.59 (38), p.16445-16450

International ed. in English, 2020

Link zum Volltext

Verfügbarkeit prüfen

Resistance to proteasome inhibitors and other targeted therapies in myeloma

British journal of haematology, 2018-07, Vol.182 (1), p.11-28

2018

Link zum Volltext

Verfügbarkeit prüfen

Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Anti‐malaria Activity in Humanized Mice

Angewandte Chemie (International ed.), 2021-04, Vol.60 (17), p.9279-9283

International ed. in English, 2021

Link zum Volltext

Verfügbarkeit prüfen

Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma

Journal of cellular and molecular medicine, 2014-06, Vol.18 (6), p.947-961

2014

Link zum Volltext

Verfügbarkeit prüfen

Bortezomib and other proteosome inhibitors—induced peripheral neurotoxicity: From pathogenesis to treatment

Journal of the peripheral nervous system, 2019-10, Vol.24 (S2), p.S52-S62

2019

Link zum Volltext

Verfügbarkeit prüfen

Synthesis and Evaluation of Derivatives of the Proteasome Deubiquitinase Inhibitor b-AP15

Chemical biology & drug design, 2015-11, Vol.86 (5), p.1036-1048

2015

Link zum Volltext

Verfügbarkeit prüfen

Synthesis and Pharmacology of Proteasome Inhibitors

Angewandte Chemie (International ed.), 2013-05, Vol.52 (21), p.5450-5488

International ed. in English, 2013

Link zum Volltext

Verfügbarkeit prüfen

Activity‐based probes for the multicatalytic proteasome

The FEBS journal, 2017-05, Vol.284 (10), p.1540-1554

2017

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment

British journal of clinical pharmacology, 2016-09, Vol.82 (3), p.728-738

2016

Link zum Volltext

Verfügbarkeit prüfen

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors)

Clinical microbiology and infection, 2018-06, Vol.24 (Suppl 2), p.S95-S107

2018

Link zum Volltext

Verfügbarkeit prüfen

A practical review on carfilzomib in multiple myeloma

European journal of haematology, 2016-06, Vol.96 (6), p.564-577

2016

Link zum Volltext

Verfügbarkeit prüfen

Procyanidin‐B2 enriched fraction of cinnamon acts as a proteasome inhibitor and anti‐proliferative agent in human prostate cancer cells

IUBMB life, 2018-05, Vol.70 (5), p.445-457

2018

Link zum Volltext

Verfügbarkeit prüfen

The immunoproteasome‐specific inhibitor ONX 0914 reverses susceptibility to acute viral myocarditis

EMBO molecular medicine, 2018-02, Vol.10 (2), p.200-218

2018

Link zum Volltext

Verfügbarkeit prüfen

Exosomes mediate intercellular transfer of non–autonomous tolerance to proteasome inhibitors in mixed‐lineage leukemia

Cancer science, 2020-04, Vol.111 (4), p.1279-1290

2020

Link zum Volltext

Verfügbarkeit prüfen

Small-Molecule Control of Intracellular Protein Levels through Modulation of the Ubiquitin Proteasome System

Angewandte Chemie (International ed.), 2014-02, Vol.53 (9), p.2312-2330

International ed. in English, 2014

Link zum Volltext

Verfügbarkeit prüfen

Effects of invivo CXCR4 blockade and proteasome inhibition on bone marrow plasma cells in HLA-sensitized kidney transplant candidates

American journal of transplantation, 2023-06, Vol.23 (6), p.759-775

2023

Link zum Volltext

Verfügbarkeit prüfen

Carfilzomib: a novel agent for multiple myeloma

Journal of pharmacy and pharmacology, 2013-08, Vol.65 (8), p.1095-1106

Redic, Kimberly

2013

Link zum Volltext

Verfügbarkeit prüfen

A prospective, iterative, adaptive trial of carfilzomib‐based desensitization

American journal of transplantation, 2020-02, Vol.20 (2), p.411-421

2020

Link zum Volltext

Verfügbarkeit prüfen

A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)

American journal of hematology, 2021-12, Vol.96 (12), p.1595-1603

2021

Link zum Volltext

Verfügbarkeit prüfen

Oxidatively modified low‐density lipoproteins are potential mediators of proteasome inhibitor resistance in multiple myeloma

International journal of cancer, 2021-06, Vol.148 (12), p.3032-3040

2021

Link zum Volltext

Verfügbarkeit prüfen

Ricolinostat (ACY‐1215) induced inhibition of aggresome formation accelerates carfilzomib‐induced multiple myeloma cell death

British journal of haematology, 2015-05, Vol.169 (3), p.423-434

2015

Link zum Volltext

Verfügbarkeit prüfen

Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma

British journal of haematology, 2018-01, Vol.180 (2), p.271-275

2018

Link zum Volltext

Verfügbarkeit prüfen

Proteasome inhibitors and Smac mimetics cooperate to induce cell death in diffuse large B‐cell lymphoma by stabilizing NOXA and triggering mitochondrial apoptosis

International journal of cancer, 2020-09, Vol.147 (5), p.1485-1498

2020

Link zum Volltext

Verfügbarkeit prüfen

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

British journal of haematology, 2012-09, Vol.158 (6), p.739-748

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.697

Suche als RSS-Feed

Aktive Filter

KollektionWiley Online Library Journals Frontfile Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.674)
Mit Volltextzugriff
(1.686)

Publikationsform

Artikel
(1.695)
Buchkapitel
(1)
Berichte
(1)

Sprache

Englisch
(1.691)
Japanisch
(451)
Deutsch
(12)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.463)
Life Sciences & Biomedicine
(1.399)
Humans
(1.019)
Animals
(702)
Proteasome Inhibitors
(688)
Biochemistry & Molecular Biology
(549)
Proteasome Endopeptidase Complex - Metabolism
(517)
Cell Biology
(460)
Proteasome
(402)
Mice
(347)
Proteasome Endopeptidase Complex
(345)
Biological And Medical Sciences
(314)
Bortezomib
(276)
Cell Line, Tumor
(274)
Male
(258)
Apoptosis
(257)
Female
(246)
Proteins
(215)
Leupeptins - Pharmacology
(214)
Medical Sciences
(212)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients

Enzymatically Formed Peptide Assemblies Sequestrate Proteins and Relocate Inhibitors to Selectively Kill Cancer Cells

Resistance to proteasome inhibitors and other targeted therapies in myeloma

Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Anti‐malaria Activity in Humanized Mice

Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma

Bortezomib and other proteosome inhibitors—induced peripheral neurotoxicity: From pathogenesis to treatment

Synthesis and Evaluation of Derivatives of the Proteasome Deubiquitinase Inhibitor b-AP15

Synthesis and Pharmacology of Proteasome Inhibitors

Activity‐based probes for the multicatalytic proteasome

Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors)

A practical review on carfilzomib in multiple myeloma

Procyanidin‐B2 enriched fraction of cinnamon acts as a proteasome inhibitor and anti‐proliferative agent in human prostate cancer cells

The immunoproteasome‐specific inhibitor ONX 0914 reverses susceptibility to acute viral myocarditis

Exosomes mediate intercellular transfer of non–autonomous tolerance to proteasome inhibitors in mixed‐lineage leukemia

Small-Molecule Control of Intracellular Protein Levels through Modulation of the Ubiquitin Proteasome System

Effects of invivo CXCR4 blockade and proteasome inhibition on bone marrow plasma cells in HLA-sensitized kidney transplant candidates

Carfilzomib: a novel agent for multiple myeloma

A prospective, iterative, adaptive trial of carfilzomib‐based desensitization

A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)

Oxidatively modified low‐density lipoproteins are potential mediators of proteasome inhibitor resistance in multiple myeloma

Ricolinostat (ACY‐1215) induced inhibition of aggresome formation accelerates carfilzomib‐induced multiple myeloma cell death

Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma

Proteasome inhibitors and Smac mimetics cooperate to induce cell death in diffuse large B‐cell lymphoma by stabilizing NOXA and triggering mitochondrial apoptosis

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

Aktive Filter

Suchergebnisse filtern